Extraordinary meeting of the Pharmacovigilance Risk Assessment Committee (PRAC): 18 March 2021
EventHumanCOVID-19Pharmacovigilance
Date
- Thursday, 18 March 2021, All day
Location
- OnlineEuropean Medicines Agency, Amsterdam, the Netherlands
This extraordinary meeting is organised in the context of the evaluation of a safety signal with COVID-19 Vaccine AstraZeneca relating to cases of thromboembolic events.
The aim of the meeting is to conclude the evaluation of the signal based on the information gathered and make any necessary recommendations for further action.
The Pharmacovigilance Risk Assessment Committee (PRAC) is the European Medicines Agency's (EMA) committee responsible for assessing and monitoring the safety of human medicines.